The coming of age of virus-like particle vaccines

Biological Chemistry - Tập 389 Số 5 - Trang 521-536 - 2008
Gary T. Jennings1, Martin F. Bachmann1
1Cytos Biotechnology AG, CH-8952 Zurich-Schlieren, Switzerland

Tóm tắt

Abstract Virus-like particles are supra-molecular assemblages, usually icosahedral or rod-like structures. They incorporate key immunologic features of viruses which include repetitive surfaces, particulate structures and induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors. They carry no replicative genetic information and can be produced recombinantly in large scale. Virus-like particles thus represent a safe and effective vaccine platform for inducing potent B- and T-cell responses. In addition to being effective vaccines against the corresponding virus from which they are derived, virus-like particles can also be used to present foreign epitopes to the immune system. This can be achieved by genetic fusion or chemical conjugation. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases. Towards this end, virus-like particles have been used to induce autoantibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer's disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development.

Từ khóa


Tài liệu tham khảo

Treanor, 1990, and Mur - phy Passively transferred monoclonal antibody to the protein inhibits influenza A virus replication in mice, Virol, 64, 1375, 10.1128/JVI.64.3.1375-1377.1990

Fifis, 2004, Size - dependent immunogenicity : therapeutic and protective prop - erties of nano - vaccines against tumors, Immunol, 173

Chackerian, 2007, Virus - like particles : flexible platforms for vaccine development Expert Rev Jennings and Bachmann Article in press - uncorrected proof Induction of autoantibodies to mouse CCR with recombinant papil - lomavirus particles, Vaccines Proc Natl Acad Sci USA, 6, 381

Jiang, 1992, Expression , self - assembly , and antigenicity of the Norwalk virus capsid protein, J Virol, 66, 6527, 10.1128/JVI.66.11.6527-6532.1992

Michel, 2004, Renin - angiotensin vaccine : old story , new project efficacy versus safety ( Lond ), Clin Sci, 107, 145, 10.1042/CS20040116

Tacket, 2003, and Humoral mucosal , and cellular immune responses to oral Norwalk virus - like particles in vol - unteers, Clin Immunol, 108, 241, 10.1016/S1521-6616(03)00120-7

Fehr, 1997, Di Padova Role of repetitive antigen patterns for induction of antibodies against antibodies, Exp Med, 185

Harding, 1994, and Phagocytic processing of exogenous particulate antigens by macrophages for pres - entation by class I MHC molecules, Immunol, 153

Pentel, 2000, et al A nicotine conjugate vaccine reduces nicotine dis - tribution to brain and attenuates its behavioral and cardio - vascular effects in rats, Pharmacol Biochem Behav, 65, 191, 10.1016/S0091-3057(99)00206-3

Ionescu, 2006, and Shi Pharmaceutical and immunological eval - uation of human papillomavirus virus - like particle as an anti - gen carrier, Pharm Sci, 95, 70, 10.1002/jps.20493

Fanger, 1996, Type I ( CD ) and type II ( CD ) Fc g receptor - mediated phagocytosis by human blood dendritic cells, Immunol, 64

Schodel, 1993, and Milich Structure of hepatitis B virus core and e - antigen A single precore amino acid prevents nucleo - capsid assembly, Biol Chem, 268

liams, 2002, and Long - term follow - up : no effect of ther - apeutic vaccination with HIV - p p : Ty virus - like particles on HIV - disease progression, Vaccine, 1, 1

Dintzis, 1982, Specific cellular stimulation in the primary immune response : experi - mental test of a quantized model de Villiers Mal - merfelt Active immunization against nicotine suppresses nicotine - induced dopamine release in the rat nucleus accumbens shell, Proc Natl Acad Sci USA Respiration, 79, 884, 10.1073/pnas.79.3.884

Gordon, 1995, der Safety immunogenicity , and effi - cacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein - hepatitis B surface antigen subunit vaccine, Infect Dis, 171

Bachmann, 1996, and The influence of virus structure on antibody responses and virus serotype formation, Immunol Today, 17, 553, 10.1016/S0167-5699(96)10066-9

Neirynck, 1999, Jou and Fiers A universal influenza A vaccine based on the extracellular domain of the protein, Med, 2, 1157

Masliah, 2005, Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease, Neurology, 64, 129, 10.1212/01.WNL.0000148590.39911.DF

Ambuhl, 2007, A vaccine for hypertension based on virus - like particles : preclinical efficacy and phase I safety and immunogenicity, Hypertens, 25, 63, 10.1097/HJH.0b013e32800ff5d6

telein, 2006, Neutraliz - ation of IL - by active vaccination inhibits IL - - dependent autoimmune myocarditis, Eur J Immunol, 17, 2849

Schenk, 1999, Gui - do et al Immunization with amyloid - beta attenuates Alzhei - mer - disease - like pathology in the PDAPP mouse Nature and Papillomavirus - like particle vaccines Cancer Inst, Monogr, 28, 400

Crook, 2002, The genetics of human hypertension Semin, Nephrol, 22, 27

Gelinas, 2004, St George and Immunotherapy for Alzheimer s disease Proc, Natl Acad Sci USA, 101, 14657, 10.1073/pnas.0404866101

Ruedl, 2002, Cross - presentation of virus - like particles by skin - derived CD dendritic cells : a dispensable role for TAP, Eur J Immunol, 8, 818, 10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U

Nicoll, 2003, and Neuropathology of human Alzheimer disease after immunization with amyloid - b peptide : a case report, Nat Med, 9, 448, 10.1038/nm840

Takeuchi, 2007, and Recognition of viruses by innate immunity, Immunol Rev, 220

Thyagarajan, 2003, Polyvalent antigens stabilize B - cell antigen receptor surface signaling microdomains, Immunol, 170

Chackerian, 2001, Conjugation of a self - antigen to papillomavirus - like particles allows for efficient induction of protective autoantibodies, Invest, 108, 415, 10.1172/JCI11849

Wang, 2002, Natural supramolecular building blocks Cysteine - added mutants of cowpea mosaic virus World Health Organization WHO - CSR , update July ( http : / / www who int / csr / don /, Chem Biol, 9, 813, 10.1016/S1074-5521(02)00166-7

Gatto, 2004, Rapid response of marginal zone B - cells to viral particles, Immunol, 173

Schwarz, 2003, Ro thlisberger Role of Toll - like receptors in co stimulating cytotoxic T - cell responses, Eur J Immunol, 33, 1465, 10.1002/eji.200323919

Bachmann, 1993, ner The influence of anti - gen organization on B - cell responsiveness, Science, 262

Storni, 2004, and Loading of MHC class I and II presentation pathways by exogenous antigens : a quantitative in vivo comparison, Immunol, 172

Bachmann, 1995, T helper cell - independent neutralizing B - cell response against vesicular stomatitis virus : role of antigen patterns in - cell induction, Eur J Immunol, 25, 3445, 10.1002/eji.1830251236

Brown, 2004, Randomized double - blind pla - cebo - controlled study of an angiotensin immunotherapeutic vaccine ( PMD ) in hypertensive subjects, Clin Sci, 107, 167, 10.1042/CS20030381

Jegerlehner, 2007, and TLR signaling in B - cells determines class switch recombination to IgG a, Immunol, 2, 9

Cooper, 2002, and Medicine at the medical center then and now : one hundred years of progress South Med, J, 95, 1113

Chackerian, 2006, Virus and virus - like particle - based immunogens for Alzheimer s disease induce antibody responses against amy - loid - beta without concomitant T - cell responses, Vaccine, 24, 6321, 10.1016/j.vaccine.2006.05.059

Slepushkin, 1995, Protection of mice against influ - enza A virus challenge by vaccination with baculovirus - expressed protein, Vaccine, 2, 1399, 10.1016/0264-410X(95)92777-Y

Peabody, 2003, A viral platform for chemical modification and multivalent display, Nanobiotechnol, 1, 5, 10.1186/1477-3155-1-5

Kazaks, 2004, Mosaic hepatitis B virus core particles presenting the complete preS sequence of the viral envelope on their surface, Gen Virol, 85, 2665, 10.1099/vir.0.79810-0

Plotkin, 2005, Vaccines : past , present and future, Med Suppl, 11

Elliott, 2003, The economic impact of hypertension, Clin Hypertens, 5, 3, 10.1111/j.1524-6175.2003.02463.x

Pumpens, 2001, and HBV core particles as a car - rier for B - cell cell epitopes Ro hn Vaccination against IL - suppresses autoimmune arthritis and enceph - alomyelitis, Intervirology Eur J Immunol, 44, 98, 10.1159/000050037

Storni, 2004, Nonmethylated CG motifs packaged into virus - like particles induce protective cytotoxic T - cell responses in the absence of systemic side effects, Immunol, 172

Hieda, 1997, Active immunization alters the plasma nicotine concentration in rats, Pharmacol Exp Ther, 283

Jegerlehner, 2002, and Bachmann a Regulation of IgG antibody responses by epitope density and CD - mediated costimu - lation Eur, J Immunol, 32, 21

Garland, 2007, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases Engl, J Med, 356

Schwarz, 2005, Efficient homologous prime - boost strategies for T - cell vaccination based on virus - like particles, Eur J Immunol, 35, 816, 10.1002/eji.200425755

Lenz, 2001, and Schiller Papillomavirus - like particles induce acute activation of dendritic cells, Immunol, 166

Poland, 2001, Influenza vaccines : a review and rationale for use in devel - oped and underdeveloped countries, Vaccine, 19, 2216, 10.1016/S0264-410X(00)00448-5

Kazaks, 2002, Stop codon insertion restores the particle formation ability of hepatitis B virus core - hantavirus nucleocapsid protein fusions, Intervirology, 45, 340, 10.1159/000067927

Burnier, 2000, Long - term compliance with antihypertensive therapy : another facet of chronotherapeutics in hypertension Blood Press, Monit Suppl, 5

Matsushita, 2001, and Fujita Ficolins and the lectin com - plement pathway, Immunol Rev, 180

Maurer, 2005, Mu ller A therapeutic vaccine for nicotine dependence : preclinical efficacy , and phase I safety and immunogenicity Eur, J Immunol, 35, 2031

Bachmann, 1997, and Neutralizing anti - viral B - cell responses, Annu Rev Immunol, 15, 235, 10.1146/annurev.immunol.15.1.235

Maurer, 2006, and Therapeutic vaccines for nicotine dependence, Curr Opin Mol Ther, 8, 11

Johnson, 2000, and Structures of virus and virus - like particles, Curr Opin Struct Biol, 10, 229, 10.1016/S0959-440X(00)00073-7

Wampler, 1985, and Multiple chemical forms of hepatitis B surface antigen produced in yeast USA, Proc Natl Acad Sci, 82, 6830, 10.1073/pnas.82.20.6830

Tissot, 2008, Vaccination against angiotensin II reduces day - time and early - morning ambulatory blood pressure : results of a randomized placebo - controlled phase IIa study with CYT - AngQb, Lancet, 006, 371

Tacket, 2000, Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes, Infect Dis, 182

Buonamassa, 2002, Yeast coexpression of human papillomavirus types and capsid proteins, Virology, 293

Kaiser, 2006, A one - size - fits - all flu vaccine, Science, 312

Walther, 2005, Safety , immunogenicity and efficacy of a pre - erythrocytic malaria candidate vaccine formulated in Seppic ISA, Vaccine, 23, 857, 10.1016/j.vaccine.2004.08.020

Staufenbiel, 2006, Lu o nd Ort - mann Immunization with Ab - coupled to the virus - like particle Qb ( CAD ) efficiently removes b - amyloid without inducing Ab - reactive T - cells Proceedings of th ICAD Alzheimer s and Dementia, Suppl, 106, 1

Krieg, 2006, Therapeutic potential of toll - like receptor activation, Nat Rev Drug Discov, 5, 9, 10.1038/nrd2059

Malin, 2001, et al Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome Phar - macol, Biochem Behav, 68, 87, 10.1016/S0091-3057(00)00436-6

Storni, 2002, Critical role for activation of antigen - presenting cells in priming of cytotoxic T - cell responses after vaccinationwith virus - like particles, Immunol, 168, 2880, 10.4049/jimmunol.168.6.2880

Gleiter, 2001, and Lilie Coupling of antibodies via protein Z on modified polyoma virus - like particles Protein, Sci, 10, 434

Jegerlehner, 2002, Ku ndig Ba chi et al A molecular assembly system that renders antigens of choice highly repetitive for induction of protective - cell responses, Vaccine, 20, 3104, 10.1016/S0264-410X(02)00266-9

Lindblom, 2002, de Active immu - nization against nicotine prevents reinstatement of nicotine - seeking behavior in rats, Respiration, 69, 254, 10.1159/000063629

Coates, 2001, Hepatitis B vaccines : assessment of the seroprotec - tive efficacy of two recombinant DNA vaccines, Clin Ther, 23, 392, 10.1016/S0149-2918(01)80044-8

Nardin, 2004, and Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes Infect, Immun, 72, 6519

Justewicz, 1995, The - cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin, Virol, 69

Grgacic, 2006, and Virus - like particles : passport to immune recognition, Methods, 40, 60, 10.1016/j.ymeth.2006.07.018

Jennings, 2007, and Designing recombi - nant vaccines with viral properties : a rational approach to more effective vaccines, Curr Mol Med, 7, 143, 10.2174/156652407780059140

Kratz, 1999, Native display of complete foreign protein domains on the surface of hepatitis B virus capsids, Proc Natl Acad Sci USA, 96, 1915, 10.1073/pnas.96.5.1915

Ulrich, 1998, Core particles of hepatitis B virus as carrier for foreign epitopes Adv Virus, Res, 50, 141